FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

Key Findings

• ●FDA approval summary for midostaurin in ASM/SM-AHN/MCL (April 2017)
• ●56% dose modifications for toxicity; 21% treatment discontinuation

Referenced in (1 disease)

No validation events recorded yet. Source will be checked on the next kipine-source-validator run.